Home » Topics » BioWorld Science

BioWorld Science
RSS

RTI International discovers new APLNR agonists

May 4, 2018

Phase III trial of ranibizumab biosimilar FYB-201 meets primary endpoint

May 4, 2018

Sanofi reviews key events of first quarter 2018

May 4, 2018

Jiangsu Hengrui Medicine and collaborator disclose TGFR-1 inhibitors

May 4, 2018

AbbVie divulges novel BRD4 inhibitors

May 4, 2018

Ferring Pharmaceuticals acquires option to commercialize nadofaragene firadenovec/Syn3

May 4, 2018

Bristol-Myers Squibb presents new apelin receptor agonists

May 4, 2018

Ocular Therapeutix doses first patient in phase I clinical trial of OTX-TIC

May 4, 2018

FDA grants two fast track designations for 5F9

May 4, 2018

RBH-61, a dual SEH/PDE inhibitor for inflammatory pain

May 4, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 6, 2026.
CINP 2026: Prenatal and adolescent stress shape brain vulnerability
BioWorld Science
Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...
Ontrack Therapeutics divulges compounds for neurodegenerative diseases
BioWorld Science
Ontrack Therapeutics Ltd. has reported new heterotricyclic compounds potentially useful for the treatment of neurodegenerative diseases.
Neuracle eyes Shanghai IPO as global BCI funding surges
BioWorld
Neuracle Medical Technology Co. Ltd. is seeking a Shanghai IPO that could make it China’s first publicly listed invasive brain-computer interface (BCI) company,...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...